Preserved Ejection Fraction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. In this randomized controlled trial, long-term beta-blockers did not impact all-cause mortality among patients with preserved left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) and early angiography. 2. Long-term beta-blocker therapy was not associated with a higher risk of adverse events compared to no beta-blocker. Evidence Rating Level: 1 (Excellent) Study

1. In this randomized controlled trial, semaglutide was more effective in reducing heart failure-related symptoms and physical limitations in patients with obesity-related heart failure and type 2 diabetes mellitus (T2DM) than placebo. 2. Patients with obesity-related heart failure and T2DM exhibited greater weight loss with semaglutide than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.

Wegovy, a popular weight loss drug, seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to a new study.

BETHESDA, Md.--(BUSINESS WIRE)--Apr 7, 2024--